A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

June 16, 2008

Scoring Tool Helps Predict KS Worsening

A simple scoring tool is able to predict which HIV-positive patients with the AIDS-related Kaposi’s sarcoma (KS) are most likely to see their cancer progress, according to a study published in the May 31 issue of AIDS, and reported by AIDSmap.

KS, which is caused by the human herpes virus-8 (HHV-8), was once a common skin cancer in people with HIV. Though antiretroviral (ARV) treatment is one of the most effective measures a person can take to keep KS at bay, a small percentage of people develop new lesions or worsening KS symptoms despite the use of ARV therapy. And until recently, there haven’t been any tools to help predict which HIV-positive people with KS are likely to respond well to ARV treatment alone or those who will require therapy specifically for their lesions.

In designing such a tool, Emmanuelle Boffi El Amari, MD, from the Geneva University Hospital in Switzerland, and her colleagues found three variables that increased the risk for KS disease progression, after conducting an analysis of stored blood samples from 144 patients diagnosed with KS in the Swiss HIV Cohort study.

The first variable was disease staging. As might be expected, those initially diagnosed with more widespread and aggressive symptoms, classified as disease stage T1, were five times more likely to have disease progression than those classified with the less severe disease stage T0.

Second, people with a CD4 count of less than 200 were twice as likely as people with a higher CD4 count to have KS progression. Third, people who had detectable levels of HHV-8 were also twice as likely to have KS progression as people with no detectable HHV-8.

Boffi El Amari’s team writes that going forward, physicians can give a score of two points to people with a disease stage of T1, and one point each to people with either a low CD4 count or detectable HHV-8 levels. People with a score of two or more would be most likely to have KS progression and thus, most likely to need KS chemotherapy.

Search: Kaposi’s sarcoma, KS, human herpes virus-8, HHV-8, Emmanuelle Boffi El Amari, Geneva University Hospital


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    ht2988
    Kalamazoo
    Michigan


    Sin_Grinder
    Genoa
    Nevada


    sefarady
    Los Angeles
    California


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.